Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma

As the first oral multi-target anti-tumor drug proved for the treatment of patients with advanced liver cancer in 2007, sorafenib has changed the landscape of advanced hepatocellular carcinoma (HCC) treatment. However, drug resistance largely hinders its clinical application. Non-coding RNAs (ncRNAs...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Yongting, Feng, Bing, Abudoureyimu, Mubalake, Zhi, Yingru, Zhou, Hao, Wang, Ting, Chu, Xiaoyuan, Chen, Ping, Wang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848262/
https://www.ncbi.nlm.nih.gov/pubmed/31750247
http://dx.doi.org/10.3389/fonc.2019.01156
_version_ 1783469059952607232
author Lai, Yongting
Feng, Bing
Abudoureyimu, Mubalake
Zhi, Yingru
Zhou, Hao
Wang, Ting
Chu, Xiaoyuan
Chen, Ping
Wang, Rui
author_facet Lai, Yongting
Feng, Bing
Abudoureyimu, Mubalake
Zhi, Yingru
Zhou, Hao
Wang, Ting
Chu, Xiaoyuan
Chen, Ping
Wang, Rui
author_sort Lai, Yongting
collection PubMed
description As the first oral multi-target anti-tumor drug proved for the treatment of patients with advanced liver cancer in 2007, sorafenib has changed the landscape of advanced hepatocellular carcinoma (HCC) treatment. However, drug resistance largely hinders its clinical application. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), and long non-coding (lncRNAs), have recently been demonstrated playing critical roles in a variety of cancers including HCC, while the mechanisms of ncRNAs in HCC sorafenib resistance have not been extensively characterized yet. Herein, we summarize the mechanisms of recently reported ncRNAs involved in sorafenib resistance and discuss the potential strategies for their application in the battle against HCC.
format Online
Article
Text
id pubmed-6848262
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-68482622019-11-20 Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma Lai, Yongting Feng, Bing Abudoureyimu, Mubalake Zhi, Yingru Zhou, Hao Wang, Ting Chu, Xiaoyuan Chen, Ping Wang, Rui Front Oncol Oncology As the first oral multi-target anti-tumor drug proved for the treatment of patients with advanced liver cancer in 2007, sorafenib has changed the landscape of advanced hepatocellular carcinoma (HCC) treatment. However, drug resistance largely hinders its clinical application. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), and long non-coding (lncRNAs), have recently been demonstrated playing critical roles in a variety of cancers including HCC, while the mechanisms of ncRNAs in HCC sorafenib resistance have not been extensively characterized yet. Herein, we summarize the mechanisms of recently reported ncRNAs involved in sorafenib resistance and discuss the potential strategies for their application in the battle against HCC. Frontiers Media S.A. 2019-11-05 /pmc/articles/PMC6848262/ /pubmed/31750247 http://dx.doi.org/10.3389/fonc.2019.01156 Text en Copyright © 2019 Lai, Feng, Abudoureyimu, Zhi, Zhou, Wang, Chu, Chen and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lai, Yongting
Feng, Bing
Abudoureyimu, Mubalake
Zhi, Yingru
Zhou, Hao
Wang, Ting
Chu, Xiaoyuan
Chen, Ping
Wang, Rui
Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
title Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
title_full Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
title_fullStr Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
title_full_unstemmed Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
title_short Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
title_sort non-coding rnas: emerging regulators of sorafenib resistance in hepatocellular carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848262/
https://www.ncbi.nlm.nih.gov/pubmed/31750247
http://dx.doi.org/10.3389/fonc.2019.01156
work_keys_str_mv AT laiyongting noncodingrnasemergingregulatorsofsorafenibresistanceinhepatocellularcarcinoma
AT fengbing noncodingrnasemergingregulatorsofsorafenibresistanceinhepatocellularcarcinoma
AT abudoureyimumubalake noncodingrnasemergingregulatorsofsorafenibresistanceinhepatocellularcarcinoma
AT zhiyingru noncodingrnasemergingregulatorsofsorafenibresistanceinhepatocellularcarcinoma
AT zhouhao noncodingrnasemergingregulatorsofsorafenibresistanceinhepatocellularcarcinoma
AT wangting noncodingrnasemergingregulatorsofsorafenibresistanceinhepatocellularcarcinoma
AT chuxiaoyuan noncodingrnasemergingregulatorsofsorafenibresistanceinhepatocellularcarcinoma
AT chenping noncodingrnasemergingregulatorsofsorafenibresistanceinhepatocellularcarcinoma
AT wangrui noncodingrnasemergingregulatorsofsorafenibresistanceinhepatocellularcarcinoma

Ejemplares similares